# AC Immune (ACIU) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ACIU
## Company Profile
- Ticker: ACIU
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Switzerland and listed in the U
- Tags: Immunotherapy, CNS
## Stock Data
- Close: 2.62 USD
- Market cap: 246292046.66 USD
- Last updated: 2026-08-12
## Business Overview
### Precision Neurodegeneration
AC Immune develops therapeutics and diagnostics for neurodegenerative diseases driven by protein misfolding and inflammation. Its portfolio combines active immunotherapies, small molecules and PET imaging agents.
### ACI-7104
ACI-7104 is an active immunotherapy targeting alpha-synuclein in early Parkinson’s disease. Interim Phase 2 VacSYn results showed strong immunogenicity and suggested a potential slowing of clinical progression.
### Alzheimer’s Immunotherapies
ACI-24 is an anti-amyloid active immunotherapy in the Phase 2 ABATE trial, while ACI-35 targets pathological tau. Both programs form part of AC Immune’s partnered clinical-stage vaccine portfolio.
### Morphomer Small Molecules
The Morphomer platform creates brain-penetrant small molecules targeting intracellular protein pathology. Programs include tau aggregation inhibitors and ACI-19764, an NLRP3 inflammasome inhibitor now in Phase 1 testing.
### Diagnostic Tracers
AC Immune also develops PET tracers for neurodegenerative pathology, including TDP-43. These tools could improve patient selection and disease monitoring in conditions that currently lack specific imaging biomarkers.
## Why The Stock Is Moving

Following the latest company update, “AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)”, ACIU closed up 11.4% at $2.54 on Aug 11, 2026. The move occurred in the trading session associated with this fda / regulatory update.

## Future Catalysts

- Interim Phase 2 ABATE results from the ACI-24 AD3 cohort expected in the first half of 2026.
- Final Part 1 VacSYn data for ACI-7104 expected in mid-2026, including full 24-month data in the third quarter.
- IND-enabling studies for the Morphomer-Tau program expected to begin in the first half of 2026.

## Recent News
- 2026-08-11 11:00 EST — [AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)](https://biopharmsignal.com/news/ACIU/ac-immune-receives-fda-fast-track-designation-for-anti-alpha-synuclein-active-im-87ff9960) — Source: AC Immune
- 2026-08-05 11:00 EST — [AC Immune First Half 2026 Financial and Corporate Update](https://biopharmsignal.com/news/ACIU/ac-immune-first-half-2026-financial-and-corporate-update-148e97d7) — Source: AC Immune
- 2026-07-07 11:00 EST — [AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026](https://biopharmsignal.com/news/ACIU/ac-immune-to-showcase-neurodegenerative-disease-pipeline-with-three-presentation-edc83995) — Source: AC Immune
- 2026-06-30 11:00 EST — [AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease](https://biopharmsignal.com/news/ACIU/ac-immune-reports-interim-12-month-data-from-phase-1b-2-abate-trial-of-aci-24-in-aa4acde5) — Source: AC Immune
- 2026-06-11 11:00 EST — [AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease](https://biopharmsignal.com/news/ACIU/ac-immune-to-receive-research-grant-from-goradia-family-for-development-of-aci-7-f87fb9a8) — Source: AC Immune